

In Support of Overdose Prevention Centers: Position Statement of AMERSA, Inc. (Association for Multidisciplinary Education and Research in Substance use and Addiction)

Authors

Katherine Dunham, MPH¹

Katherine Hill, MPH²

Hannah Kazal, MD, ScM³

Jenna L. Butner, MD⁴

Ilana Hull, MD, MSc⁵

Kimberly Sue, MD, PhD⁴

Li Li, MD, PhD⁶

Kristin Doneski⁷

Beth Dinges, PharmD⁸

Tessa Rife-Pennington^{9, 10}

Sunny Kung, MD¹¹

Kinna Thakarar, DO, MPH^{12,13,14,15}

Affiliations

¹ Department of Epidemiology, Brown University School of Public Health, Providence, RI, USA

² Department of Epidemiology of Microbial Diseases, Yale School of Public Health, New Haven, CT, USA

³ Division of Addiction Medicine, Department of Family Medicine, Maine Medical Center, Portland, ME, USA

⁴ Department of General Internal Medicine, School of Medicine, Yale University, New Haven, CT, USA

⁵ Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

⁶ Department of Psychiatry and Behavioral Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA

⁷ Harm Reduction Program / Needle Exchange, Portland Public Health, Portland, ME, USA

⁸ Pharmacy Service, Veteran Affairs Illiana Healthcare System, Danville, IL

⁹ Pharmacy Service, San Francisco Veterans Affairs Health Care System, San Francisco, CA, USA.

¹⁰ School of Pharmacy, University of California, San Francisco, San Francisco, CA, USA.

¹¹ Mass General Brigham Community Physicians, Haverhill, MA, USA

¹² Center for Interdisciplinary Population & Health Research/Maine, Portland, ME, USA

¹³ Department of Medicine, Maine Medical Center, Portland, ME, USA

¹⁴ Tufts University School of Medicine, Boston, MA, USA

¹⁵ Maine Medical Partners Adult Infectious Diseases, South Portland, ME, USA

Author Disclosures: The opinions expressed in this article represent those of AMERSA and the authors, not necessarily the institutions they are affiliated with.

Position statements clarify key issues that are in alignment with the vision, mission, and values of AMERSA, Inc. This Position Statement, endorsed by their Board of Directors on March 7, 2024 amplifies the position of the organization, guides their activities, and informs the public and policy makers on the organization's stance on this issue.

Executive Summary

Given increasing rates of fatal overdoses in the United States (US) and the rapidly changing drug supply, overdose prevention centers (also known as safe consumption sites) have been identified as a vital, evidence-based strategy that provide people who use drugs' (PWUD) the opportunity to use drugs safely and receive immediate, life-saving overdose support from trained personnel. In addition to providing a safe, supervised space to use drugs, overdose prevention centers (OPCs) can house further essential harm reduction drop-in services such as sterile supplies, social services, and medical care. There are established national and international data demonstrating the lifesaving services provided by OPCs, inspiring a groundswell of advocacy efforts to expand these programs in the US. Thus, the Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA) endorses OPCs, in addition to other harm reduction strategies that protect PWUD. Ultimately, it is imperative to increase access to OPCs across the US and support key policy changes at the local, state, and federal levels that would facilitate urgent expansion.

Background

In 2021, more than 106,000 Americans died of drug-related overdoses, a 14% increase from the year prior.¹ Infectious diseases among those who use drugs (e.g., hepatitis C virus (HCV), human immunodeficiency virus (HIV), infective endocarditis) have also been rising nationally and continue to be of concern.²⁻⁴ In this context, overdose prevention centers (OPCs) are a vital resource.⁵ OPCs provide supervised, safe places for people to use drugs, immediate overdose prevention services, and linkages to health and wellness services. In OPCs, people are able to use their pre-obtained drugs in the presence of trained staff who can intervene in the event of an overdose or other health emergency. Globally, these spaces are also known by other names — such as safe consumption sites, safe injection sites, or harm reduction centers — and are often co-located within larger harm reduction drop-in centers. Herein, we will utilize the term “overdose prevention center” because of the widespread use of the term nationally and the existing literature recommending such phrasing.⁶⁻⁹

The Association for Multidisciplinary Education and Research in Substance Use and Addiction (AMERSA), endorses harm reduction strategies that protect persons who use drugs. This position statement has been developed on behalf of the AMERSA Board of Directors.

OPC Operations

OPCs operate in many different ways based on the needs of their clients and local communities. Existing OPCs, for example, have operated out of tents,¹⁰ have been integrated into existing brick-and-mortar harm reduction organizations,¹¹ and have been located inside of hospitals.¹² Mobile sites have also operated out of vans or buses, bringing overdose prevention services directly to high priority locations.^{13,14} Furthermore, some sites have tailored their services to

specific populations, acknowledging that these populations face unique barriers when trying to access harm reduction services. For example, SisterSpace in Vancouver, an OPC exclusively for women and non-binary individuals, has been designed and implemented to address gender-based discrimination and violence.¹⁵ Additionally, OPCs can operate under a variety of staffing models based on available resources and client preferences. Staff at existing OPCs have included healthcare professionals (i.e. nurses, paramedics), counselors, as well as staff with lived or living experience of substance use.¹⁴ Notably, OPC clients have felt that having staff members with lived experience improves comfortability in the space.¹⁰ Finally, OPCs can offer many different health services based on clients' needs and preferences, including safer use equipment and education,¹⁴ drug checking services,¹⁶ and connection to other healthcare services (e.g. substance use treatment, primary care, mental health, sexual health services, HIV and HCV testing and treatment, wound care, etc.^{14,17}).

OPCs In Context

Globally, OPCs have existed for over 30 years – whether sanctioned or unsanctioned by local governments – and are currently operating in at least 16 countries.^{18,19} Insite, the first sanctioned site in North America, opened in Vancouver in 2003.²⁰ Currently, two sanctioned OPCs are operating in New York City, and two states — Rhode Island and Minnesota — have legalized OPCs at the state level. In other locations across the US, unsanctioned sites are also providing lifesaving care.^{21–23}

While OPCs will not be a panacea for the ongoing overdose crisis, they are an important tool in our larger harm reduction toolbox. There are numerous complementary approaches that similarly support PWUD's ability to use safely — the creation of a safer supply, drug decriminalization, telephone and digital-based overdose monitoring services like Never Use Alone and the Massachusetts Overdose Prevention Helpline, community-based drug checking services, and syringe service programs — all of which should be promoted.^{24–33}

Public Health Outcomes of OPCs

In the absence of randomized controlled trials on OPCs, current evidence about their efficacy and potential causal effects are inferred from associations discovered during quasi-experimental studies and observational studies, and theorized from descriptive studies.³⁴ Through such research, OPCs have consistently demonstrated – for decades – **overwhelmingly favorable outcomes related to overdose.**^{21,35–42} For example, at The Molson, an OPC in Vancouver that had almost 130,000 visits from September 2017 to August 2019, not only did no fatalities occur, but 770 overdoses were reversed.¹⁶ This benefit has also been found in US-based OPCs, with OnPoint NYC averting 636 overdoses during their first year of operation.⁴³ During this time, the majority (83%) of opioid overdoses were resolved without naloxone and, rather, utilized protocol-based response strategies (oxygenation, agitation, monitoring, etc.) that do not induce precipitated withdrawal.⁴³ Furthermore, OPCs' overdose prevention benefits may extend to the surrounding community. For example, at an OPC in Vancouver, authors found a statistically significant reduction in fatal overdoses within 500 meters of the site but not in other parts of the city.³⁷ The implementation of OPCs has also been associated with a significant decrease in ambulance attendances at opioid-related overdoses in the community.⁴⁴

OPCs contribute to **numerous positive public health outcomes** beyond overdose prevention, as PWUD can readily access harm reduction services, medical care referrals, and social connection in these spaces. Some of these positive public health outcomes are described below:

- Reduced Transmission of Infectious Diseases: Numerous studies have demonstrated that OPCs are associated with safer use practices, largely because OPCs can provide PWUD access to harm reduction supplies (i.e., sterile syringes, alcohol wipes, sterile water, sharps containers for used syringes, etc.) in a safe and hygienic environment (i.e., sanitized surfaces, protected settings without fear of violence or arrest, etc.) where individuals can take their time to use in a sterile fashion.⁴⁵ The provision of safer use supplies to PWUD reduces the risk of acquiring drug use-associated infections, such as HIV and HCV, as well as skin and soft tissue infections and endocarditis.^{46–49} As such, multiple studies have shown improved infectious disease related outcomes among those with access to an OPC.^{42,50–52} Additionally, OPCs facilitate opportunities for (a) education from trained staff on safer use practices and vein care, (b) connections to testing and treatment for infectious diseases such as HIV and HCV, and (c) screening for other infections such as STIs.⁴⁵
- Increased Access to Healthcare Services: Not only does data show decreased emergency care utilization and hospitalizations among PWUD who access OPCs,⁵³ but these centers can improve access to additional healthcare services through care provided on-site or by referral.^{17,42,54,55} Of note, if clients are interested, OPCs can facilitate connections to substance use treatment (e.g., medications for opioid use disorder, counseling services, etc.) and medical withdrawal management.^{54,56–58} This has been a key outcome of OPCs, as has subsequent cessation of injection drug use – identified during follow-up evaluations of OPC outcomes.^{36,54} Moreover, with the increased prevalence of xylazine-contaminated fentanyl across the US, many PWUD need access to wound care services given the debilitating nature of xylazine-associated wounds.^{59–61} Given that OPCs are healthcare settings with trained staff, these environments are well positioned to address the medical consequences of an unpredictable drug supply; this is especially important for people who might not be able to access – or might feel uncomfortable in – traditional medical settings due to established barriers such as the cost of care, anticipated stigma, and access to health insurance.^{62,63} Additionally, OPCs can provide broader health and wellness services to clients such as food, clothing, and showers.^{14,62}
- Improved Social Connection: OPCs create a safe, shared space for community and social connection. Access to OPCs has allowed PWUD to have an increased sense of belonging, provided a refuge from dangerous conditions on the street (e.g. assault, theft, criminalization, etc.), improved perceptions of support, and reduced feelings of stigma and shame around drug use.^{17,39,42,64–66} In addition to these significant social and mental health outcomes, having access to social support and larger networks has been found to be protective against overdose.^{67,68} One qualitative study in Ottawa, Canada found that

PWUD came to think of their OPC as a “social hub” and “safety net” where they became connected to a community that cared about them.¹⁷ However, it is important to recognize that these feelings of belonging and enhanced social connection may vary among clients. Evidence has shown that PWUD from marginalized groups (e.g., people of color, LGBTQIA+ individuals, women etc.) do not always experience such social benefits.^{15,17,69} Therefore, OPCs must identify and implement mechanisms to equitably extend these benefits to all clients.

- **Expanded Community Benefits:** Ultimately, with the improved health outcomes associated with OPCs, many studies have shown them to be cost-effective.^{52,70-73} At the community level, OPCs have also been associated with reductions in both local syringe litter and public drug use.⁷⁴⁻⁷⁷ OnPoint NYC, for example, has a community hotline to address syringe litter and/or public drug use, with a mobile team of community specialists that quickly respond to sightings of syringe litter and/or public drug use.⁴³ Importantly, it has been demonstrated numerous times that OPCs do not lead to increased drug use, crime, or drug selling in the area of the site.^{34,35,42,78-83}

Policy Options

In the United States, state legislatures have the authority to sanction an OPC’s operation, as states hold the power to make decisions that protect their citizens and public health.^{84,85} Such state power has a clear precedent, for example with the state-by-state legality of cannabis.⁸⁶ Beyond the legislature, states can utilize executive authority from the governor or commissioner of health, depending on the state’s specific laws, to create administrative action that allows an OPC.⁸⁴ The state-level sanctioning of OPCs would prevent local and state police from legally interfering with activities critical to the OPC’s success (i.e. threatening arrest for PWUD entering and exiting the OPC) and would provide protection for OPC staff. Recently, through respective state governments, both Rhode Island (2021-H 5245A, 2021-S 0016B) and Minnesota (SF2934) have sanctioned the operation of OPCs.⁸⁷⁻⁸⁹ Other states’ lawmakers, including Connecticut, Colorado, Illinois, Nevada, New Jersey, New Mexico, Massachusetts, and Vermont, are in the process of creating and advocating for legislation that would allow them to join these pioneering states in the formation of legally sanctioned OPCs. That being said, significant state-level barriers still exist; in California, for example, Governor Newsom vetoed a 2022 bill that would have authorized the establishment of OPCs in the state.⁹⁰

Additionally, some local governments have also made strides in implementing OPCs through their limited police power (i.e., ability to enact laws for the good of public health), from officials such as mayors or the city council.^{84,91,92} Locally-sanctioned OPCs such as OnPoint NYC have been successful despite lacking state-sanctioned protections through (a) assurances by law enforcement and local attorneys that no criminal prosecutions will be brought upon staff or clients, (b) involvement of health department officials, and (c) community-based buy-in through adequate and transparent communication.¹¹ Unfortunately, barriers at the local level can also impede OPCs; for instance, Philadelphia’s city council passed a bill in late 2023 that created zoning rules that significantly hinder OPCs path to implementation.⁹³

At the federal level, the Controlled Substances Act (CSA) is a federal law that prohibits (a) “illicit” drug possession (Section 844) and (b) the opening or management of a place that is created for the purpose of using an illicit drug (Section 856, or the “Crack House Statute”).^{94,95} When Safehouse, a Philadelphia-based nonprofit, announced that they planned to open an OPC in 2018, the federal government stepped in and sued this group, citing CSA Section 856.⁹⁶ *United States v. Safehouse* was taken to a district court in 2019 which ruled the OPC opening would *not* be in violation of Section 856 of the CSA.⁹⁷ Accordingly, after the Final Declaratory Judgement in 2020, Safehouse prepared to open its doors. However, just days after this judgment, a Notice of Appeal was filed by the federal government to the Court of Appeals for the Third Circuit.⁹⁸ An emergency motion to stay, which blocked Safehouse from opening their OPC, was eventually approved.⁹⁹ Subsequently, the Third Circuit court overturned the original district court decision by a 2-1 split in 2021, arguing that the OPC *would* be in violation of the CSA Section 856.¹⁰⁰ Currently, Safehouse continues to explore options in the court that would allow them to legally operate their OPC.¹⁰¹ Thus, unfortunately, whether or not an OPC has been sanctioned by a state or local government, federal laws place sanctioned OPCs under the threat of federal interference.

Ultimately, movements toward the formal sanctioning of OPCs will require sustained activism and advocacy on every level: local, state, and federal. In order to support these efforts, it is crucial that clinicians, researchers, educators, and community members stand with the decades of evidence supporting OPC implementation. Further, it remains paramount to not only codify protections for OPC clients, staff, and clinicians, but to ensure OPC sanctioning (a) does not lead to any further criminalization of drug use and (b) addresses racial inequities created by existing laws and policies. Specifically, it is imperative to combat laws created and maintained by the War on Drugs which systematically target, dehumanize, and disproportionately incarcerate people of color. Thus, the sanctioning of OPCs — which would provide newfound and unprecedented legal protection to people of color, allowing them a space to use drugs safely and free of prosecution and harassment — exists in stark opposition to the country’s historical, racialized criminalization of drug use.

AMERSA’s Position

In the context of the worsening overdose crisis and increasingly lethal drug supply, it is imperative that we support PWUD’s right to use drugs safely, supporting and expanding evidence-based harm reduction strategies such as OPCs. To do so, we must advocate for the sanctioning and expansion of OPCs in the US, leveraging our privilege and positions as leaders in our fields to increase public support for OPCs among key stakeholders (e.g., our local communities and legislators). Moreover, it is critical that we support the thoughtful, sustainable, and community-driven implementation of these programs. An OPC’s implementation and operation should be tailored to and driven by local community needs. Therefore, potential clients should be involved in all phases of the planning, design, implementation, and evaluation of these sites. Additionally, OPCs should consider operational recommendations and best practices already substantiated in both national and global contexts. Finally, principles of equity, intersectionality, and anti-racism must be prioritized in the implementation of these sites. This will involve accommodating multiple methods of use (e.g, injection and inhalation) and ensuring

that the OPC space is comfortable and accessible for marginalized populations that may face additional discrimination and risks when utilizing these services.

Recommendations

Given this evidence and the demonstrated public health benefits of OPCs, we propose that we leverage the position of AMERSA as interdisciplinary leaders in substance use education, research, care, and policy to:

- Disseminate accessible, relevant, and evidence-based information on OPCs — including data that address common misconceptions regarding their establishment and use — to key groups such as legislators, policymakers, clinicians, researchers, and community members.
- Support and advocate for the legalization and expansion of OPCs at the local, state, and federal levels.
- Prioritize the thoughtful, sustainable, and community-driven implementation and evaluation of OPCs. It will be critical that OPCs meet the needs of the specific communities they serve, involve PWUD in all phases of their design and operations, and center principles of equity, intersectionality, and anti-racism in their implementation and evaluation.
- Create opportunities for members to discuss barriers and facilitators to OPC implementation and support the dissemination of qualitative and quantitative research on OPCs via AMERSA's annual conference and official journal
- Explore and support the use of complementary overdose prevention strategies such as syringe service programs, virtual overdose monitoring services, and community-based drug checking programs.

References

1. Drug Overdose Deaths | Drug Overdose | CDC Injury Center. Centers for Disease Control and Prevention. Published August 22, 2023. Accessed December 7, 2023. <https://www.cdc.gov/drugoverdose/deaths/index.html>
2. 2022 Viral Hepatitis National Progress Report | CDC. Centers for Disease Control and Prevention. Published November 7, 2022. Accessed December 16, 2023. <https://www.cdc.gov/hepatitis/policy/npr/2022/index.htm>
3. Kadri AN, Wilner B, Hernandez AV, et al. Geographic Trends, Patient Characteristics, and Outcomes of Infective Endocarditis Associated With Drug Abuse in the United States From 2002 to 2016. *J Am Heart Assoc.* 2019;8(19):e012969. doi:10.1161/JAHA.119.012969
4. HIV & AIDS Trends and U.S. Statistics Overview. HIV.gov. Accessed January 28, 2024. <https://www.hiv.gov/hiv-basics/overview/data-and-trends/statistics>
5. Mattson CL, Tanz LJ, Quinn K, Kariisa M, Patel P, Davis NL. Trends and Geographic Patterns in Drug and Synthetic Opioid Overdose Deaths — United States, 2013–2019. *Morb Mortal Wkly Rep.* 2021;70(6):202-207. doi:10.15585/mmwr.mm7006a4
6. Overdose Prevention Centers. National Institute on Drug Abuse (NIDA). Published August 28, 2023. Accessed February 28, 2024. <https://nida.nih.gov/research-topics/overdose-prevention-centers>
7. Socia KM, Stone R, Palacios WR, Cluverius J. Focus on prevention: The public is more supportive of “overdose prevention sites” than they are of “safe injection facilities.” *Criminol Public Policy.* 2021;20(4):729-754. doi:10.1111/1745-9133.12566
8. Johnston JB, Thompson KA. The name and frame matters when it comes to public support of opioid prevention programs. *Int J Drug Policy.* 2024;123:104282. doi:10.1016/j.drugpo.2023.104282
9. Barry CL, Sherman SG, McGinty EE. Language Matters in Combatting the Opioid Epidemic: Safe Consumption Sites Versus Overdose Prevention Sites. *Am J Public Health.* 2018;108(9):1157-1159. doi:10.2105/AJPH.2018.304588
10. Foreman-Mackey A, Bayoumi AM, Miskovic M, Kolla G, Strike C. “It’s our safe sanctuary”: Experiences of using an unsanctioned overdose prevention site in Toronto, Ontario. *Int J Drug Policy.* 2019;73:135-140. doi:10.1016/j.drugpo.2019.09.019
11. Giglio RE, Mantha S, Harocopos A, et al. The Nation’s First Publicly Recognized Overdose Prevention Centers: Lessons Learned in New York City. *J Urban Health Bull N Y Acad Med.* 2023;100(2):245-254. doi:10.1007/s11524-023-00717-y
12. Nolan S, Kelian S, Kerr T, et al. Harm reduction in the hospital: An overdose prevention site (OPS) at a Canadian hospital. *Drug Alcohol Depend.* 2022;239:109608. doi:10.1016/j.drugalcdep.2022.109608
13. Mobile Overdose Prevention Unit | PHS Community Services Society. PHS. Accessed December 16, 2023. <https://www.phs.ca/program/mobile-ops-van/>
14. Speed KA, Gehring ND, Launier K, O’Brien D, Campbell S, Hyshka E. To what extent do supervised drug consumption services incorporate non-injection routes of administration? A systematic scoping review documenting existing facilities. *Harm Reduct J.* 2020;17:72. doi:10.1186/s12954-020-00414-y
15. Boyd J, Lavalley J, Czechaczek S, et al. “Bed Bugs and Beyond”: An ethnographic analysis of North America’s first women-only supervised drug consumption site. *Int J Drug Policy.* 2020;78:102733. doi:10.1016/j.drugpo.2020.102733
16. Olding M, Ivsins A, Mayer S, et al. A Low-Barrier and Comprehensive Community-Based Harm-Reduction Site in Vancouver, Canada. *Am J Public Health.* 2020;110(6):833-835. doi:10.2105/AJPH.2020.305612
17. Kerman N, Manoni-Millar S, Cormier L, Cahill T, Sylvestre J. “It’s not just injecting drugs”: Supervised consumption sites and the social determinants of health. *Drug Alcohol Depend.* 2020;213:108078. doi:10.1016/j.drugalcdep.2020.108078

18. *The Global State of Harm Reduction 2022*. Harm Reduction International; 2022. https://hri.global/wp-content/uploads/2022/11/HRI_GSHR-2022_Full-Report_Final.pdf
19. *Drug Consumption Rooms: An Overview of Provision and Evidence*. European Monitoring Centre for Drugs and Drug Addiction; 2018. Accessed October 21, 2023. https://www.emcdda.europa.eu/publications/pods/drug-consumption-rooms_en
20. Insite | PHS Community Services Society. PHS. Accessed December 14, 2021. <https://www.phs.ca/program/insite/>
21. Kral AH, Lambdin BH, Wenger LD, Davidson PJ. Evaluation of an Unsanctioned Safe Consumption Site in the United States. *N Engl J Med*. 2020;383(6):589-590. doi:10.1056/NEJMc2015435
22. Peltz J. "It keeps us safe": An NYC bathroom set up to stem overdoses. AP News. Published July 13, 2018. Accessed December 11, 2023. <https://apnews.com/article/0bd724fa18984d838b31faa757390c47>
23. Johnson S. In Act of Civil Disobedience, Activists Set Up Safe Drug Consumption Site in San Francisco. KQED. Published August 31, 2023. Accessed January 24, 2024. <https://www.kqed.org/news/11959803/in-act-of-civil-disobedience-activists-set-up-safe-drug-consumption-site-in-san-francisco>
24. Ivsins A, Boyd J, Beletsky L, McNeil R. Tackling the overdose crisis: The role of safe supply. *Int J Drug Policy*. 2020;80:102769. doi:10.1016/j.drugpo.2020.102769
25. Hill K, Dunham K, Brokos Z, et al. In Support of Community Drug Checking Programs: Position Statement of AMERSA, Inc. (Association for Multidisciplinary Education and Research in Substance use and Addiction). *Subst Use Amp Addict J*. 2024;45(1):4-9. doi:10.1177/29767342231212787
26. Rioux W, Enns B, Ghosh SM. Virtual overdose monitoring services/mobile overdose response services: estimated number of potentially averted drug poisoning fatality events by various telephone and digital-based overdose prevention/harm reduction services in North America. *Front Public Health*. 2023;11:1242795. doi:10.3389/fpubh.2023.1242795
27. Never Use Alone – No Judgment, No Shaming, No Preaching, Just LOVE! Accessed January 31, 2024. <https://neverusealone.com/>
28. Healey-Driscoll administration announces first-of-its-kind investment in overdose prevention helpline. <https://www.mass.gov/news/healey-driscoll-administration-announces-first-of-its-kind-investment-in-overdose-prevention-helpline>. Published September 26, 2023. Accessed December 6, 2023.
29. Ondocsin J, Ciccarone D, Moran L, et al. Insights from Drug Checking Programs: Practicing Bootstrap Public Health Whilst Tailoring to Local Drug User Needs. *Int J Environ Res Public Health*. 2023;20(11):5999. doi:10.3390/ijerph20115999
30. Carroll JJ, Mackin S, Schmidt C, McKenzie M, Green TC. The Bronze Age of drug checking: barriers and facilitators to implementing advanced drug checking amidst police violence and COVID-19. *Harm Reduct J*. 2022;19(1):9. doi:10.1186/s12954-022-00590-z
31. Lambdin BH, Bluthenthal RN, Wenger LD, et al. Overdose Education and Naloxone Distribution Within Syringe Service Programs - United States, 2019. *MMWR Morb Mortal Wkly Rep*. 2020;69(33):1117-1121. doi:10.15585/mmwr.mm6933a2
32. Earp BD, Lewis J, Hart CL, with Bioethicists and Allied Professionals for Drug Policy Reform. Racial Justice Requires Ending the War on Drugs. *Am J Bioeth AJOB*. 2021;21(4):4-19. doi:10.1080/15265161.2020.1861364
33. Russoniello K, Vakharia SP, Netherland J, et al. Decriminalization of drug possession in Oregon: Analysis and early lessons. *Drug Sci Policy Law*. 2023;9:205032452311674. doi:10.1177/20503245231167407
34. Caulkins JP, Pardo B, Kilmer B. Supervised consumption sites: a nuanced assessment of the causal evidence. *Addiction*. 2019;114(12):2109-2115. doi:10.1111/add.14747
35. Potier C, Laprévotte V, Dubois-Arber F, Cottencin O, Rolland B. Supervised injection

- services: what has been demonstrated? A systematic literature review. *Drug Alcohol Depend.* 2014;145:48-68. doi:10.1016/j.drugalcdep.2014.10.012
36. Kennedy MC, Hayashi K, Milloy MJ, Wood E, Kerr T. Supervised injection facility use and all-cause mortality among people who inject drugs in Vancouver, Canada: A cohort study. Tsai AC, ed. *PLOS Med.* 2019;16(11):e1002964. doi:10.1371/journal.pmed.1002964
 37. Marshall BD, Milloy MJ, Wood E, Montaner JS, Kerr T. Reduction in overdose mortality after the opening of North America's first medically supervised safer injecting facility: a retrospective population-based study. *The Lancet.* 2011;377(9775):1429-1437. doi:10.1016/S0140-6736(10)62353-7
 38. Bergamo S, Parisi G, Jarre P. Harm reduction in Italy: the experience of an unsanctioned supervised injection facility run by drug users. *Drugs Alcohol Today.* 2019;19(2):59-71. doi:10.1108/DAT-03-2018-0011
 39. Davidson PJ, Lopez AM, Kral AH. Using drugs in un/safe spaces: Impact of perceived illegality on an underground supervised injecting facility in the United States. *Int J Drug Policy.* 2018;53:37-44. doi:10.1016/j.drugpo.2017.12.005
 40. Harocopos A, Gibson BE, Saha N, et al. First 2 Months of Operation at First Publicly Recognized Overdose Prevention Centers in US. *JAMA Netw Open.* 2022;5(7):e2222149. doi:10.1001/jamanetworkopen.2022.22149
 41. Roux P, Jauffret-Roustide M, Donadille C, et al. Impact of drug consumption rooms on non-fatal overdoses, abscesses and emergency department visits in people who inject drugs in France: results from the COSINUS cohort. *Int J Epidemiol.* 2023;52(2):562-576. doi:10.1093/ije/dyac120
 42. Dow-Fleisner SJ, Lomness A, Woolgar L. Impact of safe consumption facilities on individual and community outcomes: A scoping review of the past decade of research. *Emerg Trends Drugs Addict Health.* 2022;2:100046. doi:10.1016/j.etch.2022.100046
 43. Gibson B, See K, Vargas Estrella B, Rivera S. *A Baseline Report on the Operation of the First Recognized Overdose Prevention Centers in the United States.* https://onpointnyc.org/wp-content/uploads/2023/12/ONPOINTNYC_OPCREPORT_small-web1.pdf
 44. Salmon AM, van Beek I, Amin J, Kaldor J, Maher L. The impact of a supervised injecting facility on ambulance call-outs in Sydney, Australia. *Addict Abingdon Engl.* 2010;105(4):676-683. doi:10.1111/j.1360-0443.2009.02837.x
 45. Thakarar K, Nenninger K, Agmas W. Harm Reduction Services to Prevent and Treat Infectious Diseases in People Who Use Drugs. *Infect Dis Clin North Am.* 2020;34(3):605-620. doi:10.1016/j.idc.2020.06.013
 46. Aspinall EJ, Nambiar D, Goldberg DJ, et al. Are needle and syringe programmes associated with a reduction in HIV transmission among people who inject drugs: a systematic review and meta-analysis. *Int J Epidemiol.* 2014;43(1):235-248. doi:10.1093/ije/dyt243
 47. Platt L, Minozzi S, Reed J, et al. Needle syringe programmes and opioid substitution therapy for preventing hepatitis C transmission in people who inject drugs. Cochrane Drugs and Alcohol Group, ed. *Cochrane Database Syst Rev.* 2017;2017(9). doi:10.1002/14651858.CD012021.pub2
 48. Fernandes RM, Cary M, Duarte G, et al. Effectiveness of needle and syringe Programmes in people who inject drugs – An overview of systematic reviews. *BMC Public Health.* 2017;17(1):309. doi:10.1186/s12889-017-4210-2
 49. Bushling C, Walton MT, Conner KL, et al. Syringe services programs in the Bluegrass: Evidence of population health benefits using Kentucky Medicaid data. *J Rural Health.* 2022;38(3):620-629. doi:10.1111/jrh.12623
 50. Kerr T, Tyndall M, Li K, Montaner J, Wood E. Safer injection facility use and syringe sharing in injection drug users. *Lancet Lond Engl.* 2005;366(9482):316-318. doi:10.1016/S0140-6736(05)66475-6

51. Andresen MA, Boyd N. A cost-benefit and cost-effectiveness analysis of Vancouver's supervised injection facility. *Int J Drug Policy*. 2010;21(1):70-76. doi:10.1016/j.drugpo.2009.03.004
52. Pinkerton SD. Is Vancouver Canada's supervised injection facility cost-saving? *Addiction*. 2010;105(8):1429-1436. doi:10.1111/j.1360-0443.2010.02977.x
53. Lambdin BH, Davidson PJ, Browne EN, Suen LW, Wenger LD, Kral AH. Reduced Emergency Department Visits and Hospitalisation with Use of an Unsanctioned Safe Consumption Site for Injection Drug Use in the United States. *J Gen Intern Med*. 2022;37(15):3853-3860. doi:10.1007/s11606-021-07312-4
54. DeBeck K, Kerr T, Bird L, et al. Injection drug use cessation and use of North America's first medically supervised safer injecting facility. *Drug Alcohol Depend*. 2011;113(2-3):172-176. doi:10.1016/j.drugalcdep.2010.07.023
55. Kerr T, Wood E. *Evidence and Best Practice for The Employment of Harm Reduction Activities in Programs Aimed at Controlling Communicable Diseases.*; 2007. http://www.bccdc.ca/resource-gallery/Documents/Statistics%20and%20Research/Publications/Epid/Other/Epi_HarmReduction_Pub_EvidenceandBestPractice_20090608.pdf
56. Folch C, Lorente N, Majó X, et al. Drug consumption rooms in Catalonia: A comprehensive evaluation of social, health and harm reduction benefits. *Int J Drug Policy*. 2018;62:24-29. doi:10.1016/j.drugpo.2018.09.008
57. Kimber J, Mattick RP, Kaldor J, Van Beek I, Gilmour S, Rance JA. Process and predictors of drug treatment referral and referral uptake at the Sydney Medically Supervised Injecting Centre. *Drug Alcohol Rev*. 2008;27(6):602-612. doi:10.1080/09595230801995668
58. Wood E, Tyndall MW, Zhang R, et al. Attendance at Supervised Injecting Facilities and Use of Detoxification Services. *N Engl J Med*. 2006;354(23):2512-2514. doi:10.1056/NEJMc052939
59. McFadden R, Wallace-Keeshen S, Petrillo Straub K, et al. Xylazine-associated Wounds: Clinical Experience From a Low-barrier Wound Care Clinic in Philadelphia. *J Addict Med*. Published online November 29, 2023. doi:10.1097/ADM.0000000000001245
60. Warp PV, Hauschild M, Tookes HE, Ciraldo K, Serota DP, Cruz I. *A Confirmed Case of Xylazine-Induced Skin Ulcers in a Person Who Injects Drugs in Miami, Florida, USA*. In Review; 2023. doi:10.21203/rs.3.rs-3194876/v1
61. Downton A, Doernberg M, Heiman E, et al. Recognition and Treatment of Wounds in Persons Using Xylazine: A Case Report From New Haven, Connecticut. *J Addict Med*. 2023;17(6):739-741. doi:10.1097/ADM.0000000000001198
62. Ivsins A, Warnock A, Small W, Strike C, Kerr T, Bardwell G. A scoping review of qualitative research on barriers and facilitators to the use of supervised consumption services. *Int J Drug Policy*. 2023;111:103910. doi:10.1016/j.drugpo.2022.103910
63. Heidari O, Tormohlen K, Dangerfield DT, Tobin KE, Farley J, Aronowitz SV. Barriers and Facilitators to Primary Care Engagement for People Who Inject Drugs: A Systematic Review. *J Nurs Scholarsh Off Publ Sigma Theta Tau Int Honor Soc Nurs*. 2023;55(3):605-622. doi:10.1111/jnu.12863
64. Jozaghi E, Andresen MM. Should North America's first and only supervised injection facility (InSite) be expanded in British Columbia, Canada? *Harm Reduct J*. 2013;10(1):1. doi:10.1186/1477-7517-10-1
65. Small W, Moore D, Shoveller J, Wood E, Kerr T. Perceptions of risk and safety within injection settings: Injection drug users' reasons for attending a supervised injecting facility in Vancouver, Canada. *Health Risk Soc*. 2012;14(4):307-324. doi:10.1080/13698575.2012.680950
66. Oudshoorn A, Sangster Bouck M, McCann M, et al. A critical narrative inquiry to understand the impacts of an overdose prevention site on the lives of site users. *Harm Reduct J*.

- 2021;18(1):6. doi:10.1186/s12954-020-00458-0
67. Mercer F, Miler JA, Pauly B, et al. Peer Support and Overdose Prevention Responses: A Systematic 'State-of-the-Art' Review. *Int J Environ Res Public Health*. 2021;18(22):12073. doi:10.3390/ijerph182212073
 68. Bennett A, Scheidell J, Bowles J, et al. Naloxone protection, social support, network characteristics, and overdose experiences among a cohort of people who use illicit opioids in New York City. *Harm Reduct J*. 2022;19(1). doi:10.1186/s12954-022-00604-w
 69. Ickowicz S, Grant C, Nosova E, et al. Factors Associated With the Use of Supervised Consumption Facilities Among Women Who Inject Drugs in a Canadian Setting. *J Addict Med*. 2020;14(5):e226-e232. doi:10.1097/ADM.0000000000000646
 70. Bayoumi AM, Zaric GS. The cost-effectiveness of Vancouver's supervised injection facility. *CMAJ Can Med Assoc J J Assoc Medicale Can*. 2008;179(11):1143-1151. doi:10.1503/cmaj.080808
 71. Khair S, Eastwood CA, Lu M, Jackson J. Supervised consumption site enables cost savings by avoiding emergency services: a cost analysis study. *Harm Reduct J*. 2022;19(1):32. doi:10.1186/s12954-022-00609-5
 72. Irwin A, Jozaghi E, Weir BW, Allen ST, Lindsay A, Sherman SG. Mitigating the heroin crisis in Baltimore, MD, USA: a cost-benefit analysis of a hypothetical supervised injection facility. *Harm Reduct J*. 2017;14(1):29. doi:10.1186/s12954-017-0153-2
 73. Irwin A, Jozaghi E, Bluthenthal RN, Kral AH. A Cost-Benefit Analysis of a Potential Supervised Injection Facility in San Francisco, California, USA. *J Drug Issues*. 2017;47(2):164-184. doi:10.1177/0022042616679829
 74. Wood E, Kerr T, Small W, et al. Changes in public order after the opening of a medically supervised safer injecting facility for illicit injection drug users. *CMAJ Can Med Assoc J*. 2004;171(7):731-734. doi:10.1503/cmaj.1040774
 75. Kral AH, Lambdin BH, Wenger LD, Browne EN, Suen LW, Davidson PJ. Improved syringe disposal practices associated with unsanctioned safe consumption site use: A cohort study of people who inject drugs in the United States. *Drug Alcohol Depend*. 2021;229(Pt A):109075. doi:10.1016/j.drugalcdep.2021.109075
 76. Stoltz JA, Wood E, Small W, et al. Changes in injecting practices associated with the use of a medically supervised safer injection facility. *J Public Health Oxf Engl*. 2007;29(1):35-39. doi:10.1093/pubmed/fdl090
 77. Kral AH, Davidson PJ. Addressing the Nation's Opioid Epidemic: Lessons from an Unsanctioned Supervised Injection Site in the U.S. *Am J Prev Med*. 2017;53(6):919-922. doi:10.1016/j.amepre.2017.06.010
 78. Kerr T, Small W, Moore D, Wood E. A micro-environmental intervention to reduce the harms associated with drug-related overdose: evidence from the evaluation of Vancouver's safer injection facility. *Int J Drug Policy*. 2007;18(1):37-45. doi:10.1016/j.drugpo.2006.12.008
 79. Wood E, Tyndall MW, Lai C, Montaner JS, Kerr T. Impact of a medically supervised safer injecting facility on drug dealing and other drug-related crime. *Subst Abuse Treat Prev Policy*. 2006;1(1):13. doi:10.1186/1747-597X-1-13
 80. Davidson PJ, Lambdin BH, Browne EN, Wenger LD, Kral AH. Impact of an unsanctioned safe consumption site on criminal activity, 2010–2019. *Drug Alcohol Depend*. 2021;220:108521. doi:10.1016/j.drugalcdep.2021.108521
 81. Myer AJ, Belisle L. Highs and Lows: An Interrupted Time-Series Evaluation of the Impact of North America's Only Supervised Injection Facility on Crime. *J Drug Issues*. 2018;48(1):36-49. doi:10.1177/0022042617727513
 82. Kennedy MC, Karamouzian M, Kerr T. Public Health and Public Order Outcomes Associated with Supervised Drug Consumption Facilities: a Systematic Review. *Curr HIV/AIDS Rep*. 2017;14(5):161-183. doi:10.1007/s11904-017-0363-y
 83. Salmon AM, Thein HH, Kimber J, Kaldor JM, Maher L. Five years on: What are the

- community perceptions of drug-related public amenity following the establishment of the Sydney Medically Supervised Injecting Centre? *Int J Drug Policy*. 2007;18(1):46-53. doi:10.1016/j.drugpo.2006.11.010
84. Beletsky L, Davis CS, Anderson E, Burris S. The Law (and Politics) of Safe Injection Facilities in the United States. *Am J Public Health*. 2008;98(2):231-237. doi:10.2105/AJPH.2006.103747
 85. Galva JE, Atchison C, Levey S. Public Health Strategy and the Police Powers of the State. *Public Health Rep*. 2005;120(1_suppl):20-27. doi:10.1177/00333549051200S106
 86. GONZALES V. RAICH.(SUPREME COURT OF THE UNITED STATES 2005). [https://supreme.justia.com/cases/federal/us/545/1/#:~:text=Raich%2C%20545%20U.S.%201%20\(2005\)&text=State%20laws%20permitting%20the%20medical,states%20under%20the%20Commerce%20Clause.&text=Angel%20Raich%2C%20a%20California%20resident,for%20her%20personal%20medical%20use](https://supreme.justia.com/cases/federal/us/545/1/#:~:text=Raich%2C%20545%20U.S.%201%20(2005)&text=State%20laws%20permitting%20the%20medical,states%20under%20the%20Commerce%20Clause.&text=Angel%20Raich%2C%20a%20California%20resident,for%20her%20personal%20medical%20use).
 87. *AN ACT RELATING TO HEALTH AND SAFETY - HARM REDUCTION CENTER ADVISORY COMMITTEE AND PILOT PROGRAM*. <http://webserver.rilin.state.ri.us/BillText/BillText21/Proposed21/H5245A.pdf>
 88. *AN ACT RELATING TO HEALTH AND SAFETY - HARM REDUCTION CENTER ADVISORY COMMITTEE AND PILOT PROGRAM*. https://www.google.com/search?q=2021-S+0016B&rlz=1C5CHFA_enUS915US919&oq=2021-S+0016B&gs_lcrp=EgZjaHJvbWUyBggAEEUYOTIHCAEQIRigATIHCAMQIRigATIHCAMQIRigAdlBBzlyNGowajeoAgCwAgA&sourceid=chrome&ie=UTF-8#:~:text=2021%20%2D%2D%20S%200016%20SUBSTITUTE,ri.us%20%E2%80%BA%20SenateText21
 89. *4th Engrossment: A Bill for an Act Relating to Human Services.*; 2023. https://www.revisor.mn.gov/bills/text.php?number=SF2934&version=latest&session=Is93&session_year=2023&session_number=0
 90. Wiley H. Newsom vetoes bill to set up drug overdose prevention programs in some California cities. Los Angeles Times. Published August 22, 2022. Accessed January 28, 2024. <https://www.latimes.com/california/story/2022-08-22/newsom-vetoes-bill-california-overdose-prevention-programs>
 91. Mayor de Blasio Announces Nation's First Overdose Prevention Center Services to Open in New York City. <https://www.nyc.gov/office-of-the-mayor/news/793-21/mayor-de-blasio-nation-s-first-overdose-prevention-center-services-open-new-york>. Published November 30, 2021.
 92. Richards EP, Rathbun KC. The Role of the Police Power in 21st Century Public Health: Sex *Transm Dis*. 1999;26(6):350-357. doi:10.1097/00007435-199907000-00008
 93. Snyder D, Kenworthy W. City council essentially bans safe injection sites opening in Philadelphia - CBS Philadelphia. Published September 29, 2023. Accessed January 28, 2024. <https://www.cbsnews.com/philadelphia/news/safe-injection-sites-in-philadelphia-banned/>
 94. *United States Code, 2006 Edition, Supplement 5, Title 21 - FOOD AND DRUGS, CHAPTER 13 - DRUG ABUSE PREVENTION AND CONTROL, SUBCHAPTER I - CONTROL AND ENFORCEMENT, Part D - Offenses and Penalties, Sec. 844 - Penalties for Simple Possession.*; 2012. <https://www.govinfo.gov/app/details/USCODE-2011-title21/USCODE-2011-title21-chap13-subchapl-partD-sec844>
 95. *United States Code, 2018 Edition, Supplement 4, Title 21 - FOOD AND DRUGS, CHAPTER 13 - DRUG ABUSE PREVENTION AND CONTROL, SUBCHAPTER I - CONTROL AND ENFORCEMENT, Part D - Offenses and Penalties, Sec. 856 - Maintaining Drug-Involved Premises.*; 2023. <https://www.govinfo.gov/app/details/USCODE-2022-title21/USCODE-2022-title21-chap13-subchapl-partD-sec856>

96. *UNITED STATES OF AMERICA v. SAFEHOUSE*. (United States District Court for the Eastern District of Pennsylvania 2019). <https://www.aidslawpa.org/victories/litigation/safe-house/#:~:text=Pennsylvania%20filed%20a-,civil%20lawsuit,-asking%20a%20federal>
97. *United States of America v. Safehouse; CIVIL ACTION No. 19-0519*. (United States District Court for the Eastern District of Pennsylvania 2019). <https://www.aidslawpa.org/victories/litigation/safe-house/#:~:text=S.%20District%20Judge,ruded,-that%20%E2%80%9Cthe%20ultimate>
98. *United States of America v. Safehouse; CIVIL ACTION No. 19-0519 - Notice of Appeal*. (United States District Court for the Eastern District of Pennsylvania 2020). <https://www.safehousephilly.org/us-v-safehouse/#:~:text=U.S.%20Notice%20of%20Appeal%20Filed%20in%20the%203rd%20Circuit>
99. *United States of America v. Safehouse; CIVIL ACTION No. 19-519*. (United States District Court for the Eastern District of Pennsylvania 2020). https://www.safehousephilly.org/sites/default/files/attachments/2020-06/156_OpGrStay%20e062420.pdf
100. *SAFEHOUSE, Petitioner, v. U.S. DEPARTMENT OF JUSTICE, ET AL., Respondents. On Petition for a Writ of Certiorari to the United States Court of Appeals for the Third Circuit*. (Supreme Court of the United States 2021). <https://www.supremecourt.gov/docket/docketfiles/html/public/21-276.html>
101. Safehouse: About. Accessed December 6, 2023. <https://www.safehousephilly.org/about>